MYD88 and diffuse large B-cell lymphoma: In ABC-DLBCL, the combined administration of ibrutinib with IRAK1/4 inhibitor I provided a synergistic cell-killing effect in MyD88 L265P cell lines and showed enhanced cell killing relative to either agent alone in primary MyD88 L265P cells [230].